TN2014000400A1 - L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists - Google Patents

L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists

Info

Publication number: TN2014000400A1
Authority: TN; Tunisia
Prior art keywords: diaza; spiro; dec; malate salt; crystalline forms
Prior art date: 2012-05-03

Application number

TNP2014000400A

Other languages

English (en)

Inventor

Ameet Vijay Ambarkhane

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-03

Filing date

2014-09-23

Publication date

2015-12-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48626496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000400(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-23 Application filed by Novartis Ag filed Critical Novartis Ag

2015-12-21 Publication of TN2014000400A1 publication Critical patent/TN2014000400A1/fr

Links

BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 title abstract 2
102000000393 Ghrelin Receptors Human genes 0.000 title abstract 2
108010016122 Ghrelin Receptors Proteins 0.000 title abstract 2
OQHQOOLVQDEIGL-UHFFFAOYSA-N 2-methyl-2,7-diazaspiro[4.4]nonane Chemical compound C1N(C)CCC11CNCC1 OQHQOOLVQDEIGL-UHFFFAOYSA-N 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
QHTKPCUWLWIRDY-JIENYHKXSA-N 2-amino-2-methyl-n-[(2r)-1-[(4s,5r)-2-methyl-1-oxo-4-phenyl-2,9-diazaspiro[4.5]decan-9-yl]-1-oxo-3-phenylmethoxypropan-2-yl]propanamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.C1([C@@H]2CN(C([C@@]22CN(CCC2)C(=O)[C@@H](COCC=2C=CC=CC=2)NC(=O)C(C)(C)N)=O)C)=CC=CC=C1 QHTKPCUWLWIRDY-JIENYHKXSA-N 0.000 abstract 1
WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
229940049920 malate Drugs 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Peptides Or Proteins (AREA)

TNP2014000400A 2012-05-03 2014-09-23 L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists TN2014000400A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261642116P	2012-05-03	2012-05-03
PCT/IB2013/053492 WO2013164790A1 (fr)	2012-05-03	2013-05-02	Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline

Publications (1)

Publication Number	Publication Date
TN2014000400A1 true TN2014000400A1 (en)	2015-12-21

Family

ID=48626496

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TNP2013000441A TN2013000441A1 (en)	2012-05-03	2013-10-29	3-spirocyclic piperidine derivatives as ghrelin receptor agonists
TNP2014000400A TN2014000400A1 (en)	2012-05-03	2014-09-23	L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000441A TN2013000441A1 (en)	2012-05-03	2013-10-29	3-spirocyclic piperidine derivatives as ghrelin receptor agonists

Country Status (20)

Country	Link
US (1)	US20130296358A1 (fr)
EP (1)	EP2852591A1 (fr)
JP (1)	JP2015525202A (fr)
KR (1)	KR20150003771A (fr)
CN (1)	CN104271579A (fr)
AR (1)	AR093748A1 (fr)
AU (1)	AU2013255458A1 (fr)
BR (1)	BR112014026210A2 (fr)
CA (1)	CA2867043A1 (fr)
CO (1)	CO7111286A2 (fr)
CU (1)	CU20130159A7 (fr)
EA (1)	EA201491990A1 (fr)
IL (1)	IL235215A0 (fr)
MA (1)	MA20150428A1 (fr)
PE (1)	PE20142443A1 (fr)
PH (1)	PH12014502446A1 (fr)
SG (1)	SG11201405810UA (fr)
TN (2)	TN2013000441A1 (fr)
TW (1)	TW201348235A (fr)
WO (1)	WO2013164790A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112020005992A2 (pt) *	2017-09-28	2020-09-29	Biogen Inc	novos sais
TW202321216A (zh) *	2021-07-30	2023-06-01	日商拉夸里亞創藥股份有限公司	晶形

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5936089A (en)	1995-05-29	1999-08-10	Pfizer Inc	Dipeptides which promote release of growth hormone
US6403599B1 (en)	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
AU7169696A (en)	1995-09-26	1997-04-17	Merck & Co., Inc.	3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
US6071926A (en)	1996-05-22	2000-06-06	Arch Development Corporation	Sleep quality improvement using a growth hormone secretagogue
UA64751C2 (uk)	1997-06-25	2004-03-15	Пфайзер Продактс Інк.	Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
AU7445498A (en)	1997-06-25	1999-01-04	Pfizer Inc.	Dipeptide derivatives as growth hormone secretagogues
TW544448B (en)	1997-07-11	2003-08-01	Novartis Ag	Pyridine derivatives
ZA987385B (en)	1997-08-19	2000-04-18	Lilly Co Eli	Growth hormone secretagogues.
US6329342B1 (en)	1997-08-19	2001-12-11	Eli Lilly And Company	Treatment of congestive heart failure with growth hormone secretagogues
GB9802251D0 (en)	1998-02-03	1998-04-01	Ciba Geigy Ag	Organic compounds
SK4382001A3 (en)	1998-10-02	2001-08-06	Novartis Ag	Mglur5 antagonists for the treatment of pain and anxiety
US6194578B1 (en)	1998-11-20	2001-02-27	Pfizer Inc.	Dipeptide derivatives
EP1486498A1 (fr)	1998-11-23	2004-12-15	Pfizer Products Inc.	Procédé et intermédiares pour secrétagogues d'hormone de croissance
GB9913079D0 (en)	1999-06-04	1999-08-04	Novartis Ag	Organic compounds
DOP2001000154A (es)	2000-05-25	2002-05-15	Pfizer Prod Inc	Combinación de secretagogos de hormona del crecimiento y antidepresivos
IL143690A0 (en)	2000-06-19	2002-04-21	Pfizer Prod Inc	The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
GB0028702D0 (en)	2000-11-24	2001-01-10	Novartis Ag	Organic compounds
PL363907A1 (en)	2001-03-26	2004-11-29	Novartis Ag	Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
ES2340664T3 (es)	2001-05-14	2010-06-08	Novartis Ag	Derivados de sulfonamidas.
JP3894035B2 (ja)	2001-07-04	2007-03-14	東レ株式会社	炭素繊維強化基材、それからなるプリフォームおよび複合材料
TW200306839A (en)	2002-02-06	2003-12-01	Novartis Ag	Quinazolinone derivatives and their use as CB agonists
AU2003218273A1 (en)	2002-04-10	2003-10-27	Eli Lilly And Company	Stereoselective process for the synthesis of (d)-2-amino-5-phenylpentanoic or alkyl ester thereof
US6696468B2 (en)	2002-05-16	2004-02-24	Dainippon Pharmaceutical Co., Ltd.	(s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SE0201940D0 (sv)	2002-06-20	2002-06-20	Astrazeneca Ab	New combination II
DOP2003000703A (es)	2002-09-20	2004-03-31	Pfizer	Compuestos de imidazopiradina como agonistas del receptor 5-ht4
GB0223730D0 (en)	2002-10-11	2002-11-20	Novartis Ag	Organic compounds
PE20040844A1 (es)	2002-11-26	2004-12-30	Novartis Ag	Acidos fenilaceticos y derivados como inhibidores de la cox-2
GB0302876D0 (en)	2003-02-07	2003-03-12	Novartis Ag	Organic compounds
CA2514733A1 (fr)	2003-02-28	2004-09-16	Transform Pharmaceuticals, Inc.	Compositions pharmaceutiques a base d'un co-cristal
JP2004277318A (ja)	2003-03-14	2004-10-07	Dainippon Pharmaceut Co Ltd	１−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
JP2004277319A (ja)	2003-03-14	2004-10-07	Dainippon Pharmaceut Co Ltd	１−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
EP1505064A1 (fr)	2003-08-05	2005-02-09	Bayer HealthCare AG	Dérivés de 2-aminopyrimidine
WO2005013997A1 (fr)	2003-08-12	2005-02-17	F. Hoffmann-La Roche Ag	Tetrahydroquinazolines spiro-substituees utilisees en tant qu'antagonistes du facteur de liberation de la corticotrophine (crf)
WO2005014557A1 (fr)	2003-08-12	2005-02-17	F.Hoffmann-La Roche Ag	Derives de la tetrahydroquinazoline en tant qu'antagonistes cfr
WO2005068448A1 (fr)	2003-08-29	2005-07-28	Ionix Pharmaceuticals Limited	Sulfonamides a action antagoniste sur des canaux calcium de type n
US20050070542A1 (en)	2003-09-03	2005-03-31	Hodgetts Kevin J.	5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
MXPA06002550A (es)	2003-09-03	2006-06-20	Pfizer	Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4.
BRPI0414087A (pt)	2003-09-05	2006-10-31	Neurogen Corp	composto, métodos para tratar um distúrbio, para demostrar a presença de receptores de crf em amostras de célula ou tecido, e para inibir a ligação de crf a um receptor de crf1, composição farmacêutica, e, embalagem
JP2005082508A (ja)	2003-09-05	2005-03-31	Dainippon Pharmaceut Co Ltd	２−アルコキシ−６−アミノ−５−ハロゲノ−ｎ−（１−置換−４−ピペリジニル）ピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
MXPA06002618A (es)	2003-09-09	2006-06-05	Ono Pharmaceutical Co	Antagonistas del factor de liberacion de corticotropina (crf) y compuestos heterobiciclicos.
GB0322612D0 (en)	2003-09-26	2003-10-29	Novartis Ag	Organic compounds
JP2005104896A (ja)	2003-09-30	2005-04-21	Dainippon Pharmaceut Co Ltd	２−アルコキシ−６−アミノ−５−ハロゲノピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
KR20060097024A (ko)	2003-09-30	2006-09-13	얀센 파마슈티카 엔.브이.	벤조이미다졸 화합물
US20050070527A1 (en)	2003-09-30	2005-03-31	Edwards James P.	Quinoxaline compounds
JP4842829B2 (ja)	2003-10-31	2011-12-21	武田薬品工業株式会社	含窒素縮合複素環化合物
US20090074890A1 (en)	2003-11-10	2009-03-19	Park Min K	Substituted Triazoles as Sodium Channel Blockers
US7208596B2 (en)	2003-11-25	2007-04-24	Bristol-Myers Squibb Pharma Company	Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
WO2005054239A1 (fr)	2003-12-05	2005-06-16	Bayer Healthcare Ag	Derives de 2-aminopyrimidine
US7211568B2 (en)	2003-12-18	2007-05-01	Kosan Biosciences Incorporated	9-Desoxoerythromycin compounds as prokinetic agents
JP2005206590A (ja)	2003-12-25	2005-08-04	Mitsubishi Pharma Corp	ナトリウムチャネルサイト２選択的阻害剤
PT1704146E (pt)	2004-01-07	2010-06-30	Aryx Therapeutics Inc	Compostos estereoisoméricos e processos para o tratamento de distúrbios gastrointestinais e do sistema nervoso central
EP1713797B1 (fr)	2004-01-29	2008-03-05	Pfizer, Inc.	Derives de 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide presentant une activite agoniste du recepteur 5-ht4
TW200533348A (en)	2004-02-18	2005-10-16	Theravance Inc	Indazole-carboxamide compounds as 5-ht4 receptor agonists
WO2005092882A1 (fr)	2004-03-01	2005-10-06	Pfizer Japan, Inc.	Derives de 4-amino-5-halogeno-benzamide utiles comme agonistes du recepteur 5-ht4 dans le traitement des troubles gastro-intestinaux, du systeme nerveux central, neurologiques et cardio-vasculaires
EP1574478A1 (fr)	2004-03-08	2005-09-14	Solvay Fluor GmbH	Préparation de fluorophosgènene
NZ550087A (en)	2004-03-25	2009-06-26	Janssen Pharmaceutica Nv	Imidazole compounds
JP2007530694A (ja)	2004-03-29	2007-11-01	メルク　エンド　カムパニー　インコーポレーテッド	ナトリウムチャネル遮断薬としてのビアリール置換ピラジノン
TWI351282B (en)	2004-04-07	2011-11-01	Theravance Inc	Quinolinone-carboxamide compounds as 5-ht4 recepto
WO2005115399A2 (fr)	2004-04-16	2005-12-08	Neurogen Corporation	Imidazopyrazines, imidazopyridines, et imidazopyrimidines utilisees comme ligands du recepteur crf1
GB0412768D0 (en)	2004-06-08	2004-07-07	Novartis Ag	Organic compounds
GB0412769D0 (en)	2004-06-08	2004-07-07	Novartis Ag	Organic compounds
EA200801608A1 (ru)	2004-06-15	2008-10-30	Пфайзер Инк.	Производные бензимидазолонкарбоновой кислоты
SE0401653D0 (sv)	2004-06-24	2004-06-24	Astrazeneca Ab	New compounds
WO2006023757A2 (fr)	2004-08-19	2006-03-02	University Of Virginia Patent Foundation	Nouveaux amines tricycliques, bicycliques, monocycliques et acycliques utiles comme agents bloquants puissants des canaux de sodium
GB0420424D0 (en)	2004-09-14	2004-10-20	Ionix Pharmaceuticals Ltd	Therapeutic compounds
WO2006038594A1 (fr)	2004-10-04	2006-04-13	Ono Pharmaceutical Co., Ltd.	Inhibiteur de canal de calcium de type n
GB0519957D0 (en)	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
EP1807423B1 (fr)	2004-11-05	2009-05-20	Theravance, Inc.	Composes de quinolinone-carboxamide
JP5086091B2 (ja)	2004-11-05	2012-11-28	セラヴァンス，インコーポレーテッド	５−ｈｔ４受容体アゴニスト化合物
JP2008519794A (ja)	2004-11-11	2008-06-12	アージェンタ・ディスカバリー・リミテッド	ピリミジン化合物
US20060111416A1 (en)	2004-11-24	2006-05-25	Lane Charlotte A L	Octahydropyrrolo[3,4-C]pyrrole derivatives
ATE469897T1 (de)	2004-12-22	2010-06-15	Theravance Inc	Indazolcarbonsäureamidverbindungen
EP1818061A1 (fr)	2005-12-02	2007-08-15	Charite-Universitätsmedizin Berlin	Utilisation de la ghréline pour stimuler la pousse des cheveux
CN101657436A (zh)	2007-02-09	2010-02-24	特兰齐姆制药公司	大环生长素释放肽受体调节剂及其使用方法
US7994203B2 (en)	2008-08-06	2011-08-09	Novartis Ag	Organic compounds
US8273900B2 (en)	2008-08-07	2012-09-25	Novartis Ag	Organic compounds
US8546416B2 (en) *	2011-05-27	2013-10-01	Novartis Ag	3-spirocyclic piperidine derivatives as ghrelin receptor agonists

2013
- 2013-05-02 EP EP13729090.4A patent/EP2852591A1/fr not_active Withdrawn
- 2013-05-02 CN CN201380023253.4A patent/CN104271579A/zh active Pending
- 2013-05-02 MA MA37470A patent/MA20150428A1/fr unknown
- 2013-05-02 US US13/875,556 patent/US20130296358A1/en not_active Abandoned
- 2013-05-02 TW TW102115769A patent/TW201348235A/zh unknown
- 2013-05-02 KR KR20147030325A patent/KR20150003771A/ko not_active Withdrawn
- 2013-05-02 AU AU2013255458A patent/AU2013255458A1/en not_active Abandoned
- 2013-05-02 SG SG11201405810UA patent/SG11201405810UA/en unknown
- 2013-05-02 JP JP2015509556A patent/JP2015525202A/ja active Pending
- 2013-05-02 EA EA201491990A patent/EA201491990A1/ru unknown
- 2013-05-02 CA CA2867043A patent/CA2867043A1/fr not_active Abandoned
- 2013-05-02 BR BR112014026210A patent/BR112014026210A2/pt active Search and Examination
- 2013-05-02 WO PCT/IB2013/053492 patent/WO2013164790A1/fr not_active Ceased
- 2013-05-02 PE PE2014001906A patent/PE20142443A1/es not_active Application Discontinuation
- 2013-05-06 AR ARP130101532A patent/AR093748A1/es unknown
- 2013-10-29 TN TNP2013000441A patent/TN2013000441A1/fr unknown
- 2013-11-27 CU CU2013000159A patent/CU20130159A7/es unknown
2014
- 2014-09-23 TN TNP2014000400A patent/TN2014000400A1/fr unknown
- 2014-10-20 IL IL235215A patent/IL235215A0/en unknown
- 2014-10-27 CO CO14237477A patent/CO7111286A2/es unknown
- 2014-10-31 PH PH12014502446A patent/PH12014502446A1/en unknown

Also Published As

Publication number	Publication date
PE20142443A1 (es)	2015-01-28
CU20130159A7 (es)	2014-02-28
SG11201405810UA (en)	2014-11-27
AR093748A1 (es)	2015-06-24
TN2013000441A1 (en)	2015-03-30
CO7111286A2 (es)	2014-11-10
BR112014026210A2 (pt)	2017-06-27
WO2013164790A1 (fr)	2013-11-07
PH12014502446A1 (en)	2015-01-12
CA2867043A1 (fr)	2013-11-07
EA201491990A1 (ru)	2015-02-27
CN104271579A (zh)	2015-01-07
MA20150428A1 (fr)	2015-11-30
JP2015525202A (ja)	2015-09-03
AU2013255458A1 (en)	2014-10-09
KR20150003771A (ko)	2015-01-09
TW201348235A (zh)	2013-12-01
IL235215A0 (en)	2014-12-31
US20130296358A1 (en)	2013-11-07
EP2852591A1 (fr)	2015-04-01

Publication	Publication Date	Title
EP3483143A8 (fr)	2020-04-15	Dérivés de pipéridinone comme inhibiteurs de mdm2 pour le traitement du cancer
EA201590228A1 (ru)	2015-05-29	Антагонисты 5-ht3 рецептора
EP4321513A3 (fr)	2024-05-08	Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
EA201290324A1 (ru)	2012-12-28	Киназные ингибиторы
EP4219465A3 (fr)	2023-09-27	Inhibiteurs de prmt5 et leurs utilisations
WO2011082266A3 (fr)	2011-10-13	Composés hétérocycliques substitués
TN2013000434A1 (en)	2015-03-30	Novel imidazole derivatives useful for the treatment of arthritis
CO6382126A2 (es)	2012-02-15	Compuestos heteroaromaticos fusionados y espirociclicos para el tratamiento de infecciones bacterianas
WO2009104021A3 (fr)	2009-11-12	Nouveaux polymorphes et procédés de préparation
PH12012502102A1 (en)	2013-02-11	Fused bicyclic kinase inhibitors
NZ629778A (en)	2016-03-31	C-terminal hsp90 inhibitors
PH12013502204A1 (en)	2017-10-25	3-spirocyclic piperidine derivatives as ghrelin receptor agonists
MX353209B (es)	2018-01-08	Antagonistas d2, metodos de sintesis y metodos de uso.
GEP20166444B (en)	2016-03-10	Epoxyeicosatrienoic acid analogs and methods of making and using the same
PH12013501321A1 (en)	2014-08-27	Phenoxymethyl heterocyclic compounds
WO2010049449A3 (fr)	2010-11-25	Nouveaux sels de sunitinib
PH12014502446A1 (en)	2015-01-12	L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
WO2014014794A3 (fr)	2015-07-16	Antagonistes des récepteurs aux minéralocorticoïdes
EA201170736A1 (ru)	2011-12-30	Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина
MX2012003394A (es)	2012-08-15	Analogos de la nicotinamida de o-bencilo como moduladores alostéricos positivos del mglur5.
MX2011008857A (es)	2011-09-30	Derivados de oxiindol con actividad agonistica del receptor de motilina.
WO2010146595A3 (fr)	2013-02-07	Nouveaux polymorphes d'hydrochlorure de flibansérine
MY179041A (en)	2020-10-26	Crystalline forms of a 3-carboxypropyl-aminotetralin compound
WO2015114660A8 (fr)	2016-08-04	Nouveaux composés hétérocycliques utilisés comme agonistes opioïdes kappa
PH12013500945A1 (en)	2013-07-08	Crystalline forms of an alkoxymidazol-1-ylmethyl-biphenyl carboxylic acid